Publication | Closed Access

An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension

HypertensionPulmonary Arterial HypertensionPulmonary CirculationMedicinePhysiologyPulmonary PharmacologyVascular BiologyPharmacotherapyPotential CarcinogenicityPharmacologyPreclinical ToxicityPulmonary Vascular Disease